Unspecified immune checkpoint protein

The term 'Unspecified immune checkpoint protein' refers to a generic or undisclosed member of the immune checkpoint family, which are cell surface molecules that play a pivotal role in regulating the immune system's response to self and non-self antigens (Pardoll, D. M., 2012, Nature Reviews Cancer). These proteins act as 'brakes' to prevent overactive immune responses and maintain self-tolerance, but they are often exploited by tumor cells to evade immune detection and destruction (NCI Dictionary of Cancer Terms, 2023). Therapeutic strategies involving checkpoint inhibitors, such as monoclonal antibodies, target these proteins to restore the anti-tumor activity of T-cells (Sharma, P., & Allison, J. P., 2015, Science). Common specific targets within this class include Programmed cell death protein 1 (PD-1) and Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Because this entry is unspecified, it represents a broad therapeutic class rather than a single molecular entity, and its clinical application is associated with a unique profile of immune-related adverse events (irAEs) resulting from systemic immune activation (Postow, M. A., et al., 2018, New England Journal of Medicine).

Other names

Immune checkpointCheckpoint proteinImmune regulator

Modulation of immune cell activity through the inhibition or stimulation of regulatory signaling pathways.